ABOUT ENZYCHEM LIFESCIENCES
Enzychem Lifesciences (KOSDAQ:183490) is developing novel small molecule therapeutics to target fundamental pathways in inflammation, patients with significant unmet needs in oncology, inflammatory, and severe respiratory diseases. Based on more than two decades of research, we developed our leading candidate EC-18(Mosedipimod), an oral small molecule derived from Sika deer antler, which has shown to be active across a number of different indications.
LIPID MEDICINE PLATFORM TECHNOLOGY
EC-18 targets anti-inflammatory
pathway
Broad therapeutic platform
Developing first-in-class small molecules to target
fundamental inflammation pathways
EC-18 PIPELINE
DEVELOPMENT STAGE
CRIOM: Chemoradiation-induced Oral Mucositis
CIN: Chemotherapy-induced Neutropenia
ARS: Acute Radiation Syndrome
COVID-19: Coronavirus Disease-19
ICI: Immune Checkpoint Inhibitors (PD-1, PD-L1)
NASH: Non-alcoholic Steatohepatitis
Press Releases
admin
March 2, 2022
Press Release
Enzychem Lifesciences Announces Formation of Corporate Advisory Committee
N.J.–(BUSINESS WIRE)–Enzychem Lifesciences (KOSDAQ: 183490), a clinical-stage biotechnology company, announced today the formation of its Corporate Advisory Committee.
admin
November 21, 2021
Press Release
Enzychem to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea
SEOUL, South Korea & AHMEDABAD, India & ENGLEWOOD CLIFFS, N.J.–(BUSINESS WIRE)–Enzychem Lifesciences(KOSDAQ: 183490) and Cadila Healthcare Ltd, a part of the Zy
admin
November 8, 2021
Press Release
Enzychem Files for FDA Breakthrough Therapy Designation for EC-18 for the Treatment of Chemoradiation-Induced Oral Mucositis
ENGLEWOOD CLIFFS, N.J.–(BUSINESS WIRE—Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biotechnology company, announced today that the Company has filed for Breakth